Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Julie R. Brahmer | Researchclopedia

Back to researchers

Julie R. Brahmer

Bloomberg (United States)ORCID

822

Works

122,656

Citations

115

h-index

329

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics

Affiliations

University of Southern California2009–2009

Uppsala University2005–2006

University of Maryland, Baltimore2007–2007

Indiana University Health2017–2017

Translational Genomics Research Institute2011–2011

Top Works

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian,F. Stephen Hodi,et al.

201212,535 citations

Colorectal Cancer Treatments and Studies

Lung Cancer Research Studies

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck,Delvys Rodríguez‐Abreu,et al.

20169,921 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei,L. Paz-Ares,et al.

20159,393 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer,Karen L. Reckamp,et al.

20158,495 citations

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer,Scott S. Tykodi,et al.

20127,944 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Alan Sandler,Robert J. Gray,et al.

20065,762 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer,Christina Lacchetti,et al.

20183,623 citations

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann,Tudor–Eliade Ciuleanu,et al.

20183,116 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer,Charles G. Drake,et al.

20102,913 citations